Literature DB >> 15308518

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

K Forslind1, M Ahlmén, K Eberhardt, I Hafström, B Svensson.   

Abstract

OBJECTIVE: To investigate the role of anti-cyclic citrullinated peptide antibody (anti-CCP) for the prediction of radiological outcome in patients with early rheumatoid arthritis.
METHODS: Anti-CCP was assessed at baseline in 379 patients with early rheumatoid arthritis (disease duration <1 year). Radiological joint damage and progression were assessed by Larsen score after two years of follow up (end point) and used as outcome variables. The prognostic value of anti-CCP and other demographic and disease related baseline variables were assessed by univariate and multivariate analyses, including calculation of odds ratios (OR), predictive values, and multiple logistic regression models.
RESULTS: The presence of anti-CCP was associated with significantly higher Larsen score both at baseline and at end point. Univariate predictor analysis showed that anti-CCP had the highest significant OR for radiological joint damage and progression after baseline Larsen score, followed by rheumatoid factor, erythrocyte sedimentation rate (ESR), C reactive protein, age, smoking status, and sex. In stepwise multiple regression analyses, baseline Larsen score, anti-CCP, and ESR were selected as significant independent predictors of the radiological outcomes.
CONCLUSIONS: There is good evidence for an association of anti-CCP with radiological joint changes in rheumatoid arthritis. Anti-CCP is an independent predictor of radiological damage and progression. Though prediction in early rheumatoid arthritis is still far from perfect, the use of anti-CCP in clinical practice should make it easier for rheumatologists to reach judicious treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308518      PMCID: PMC1755129          DOI: 10.1136/ard.2003.014233

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

Review 1.  Influence of cigarette smoking on disease outcome in rheumatoid arthritis.

Authors:  Beverley J Harrison
Journal:  Curr Opin Rheumatol       Date:  2002-03       Impact factor: 5.006

2.  Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy.

Authors:  B Svensson; C Schaufelberger; A Teleman; J Theander
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

3.  How to interpret radiological progression in randomized clinical trials?

Authors:  R B M Landewé; M Boers; D M F M van der Heijde
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

4.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

5.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.

Authors:  Henk Visser; Saskia le Cessie; Koen Vos; Ferdinand C Breedveld; Johanna M W Hazes
Journal:  Arthritis Rheum       Date:  2002-02

Review 6.  Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years.

Authors:  B Harrison; D Symmons
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

Review 7.  Prognostic factors in early rheumatoid arthritis.

Authors:  D L Scott
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

8.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

9.  Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis.

Authors:  Christian Vincent; Leonor Nogueira; Mireille Sebbag; Sabine Chapuy-Regaud; Michel Arnaud; Odile Letourneur; Dominique Rolland; Bernard Fournié; Alain Cantagrel; Michel Jolivet; Guy Serre
Journal:  Arthritis Rheum       Date:  2002-08

10.  An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis.

Authors:  S Genevay; G Hayem; P Verpillat; O Meyer
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

View more
  138 in total

1.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile?

Authors:  Banerjee Arnab; Ghosh Biswadip; Pande Arindam; Mandal Shyamash; Ghosh Anirban; Palui Rajan
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

2.  Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis.

Authors:  Toshihiro Matsui; Kota Shimada; Shigeto Tohma
Journal:  Clin Rheumatol       Date:  2005-11-10       Impact factor: 2.980

3.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 4.  [Early diagnosis of rheumatoid arthritis].

Authors:  M Schneider; B Ostendorf; C H Specker
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

5.  Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

Review 6.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 7.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 8.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

9.  High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.

Authors:  Francesca Bobbio-Pallavicini; Roberto Caporali; Claudia Alpini; Stefano Avalle; Oscar M Epis; Catherine Klersy; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2006-11-01       Impact factor: 19.103

10.  Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

Authors:  Benedicte A Lie; Marte K Viken; Sigrid Odegård; Désirée van der Heijde; Robert Landewé; Till Uhlig; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.